No Data
No Data
Zhitong Hong Kong stock short position statistics | April 28
Zhitong Hong Kong Stock Short Position Holding | April 28
Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025
BofA Securities Maintains Zai Lab(ZLAB.US) With Hold Rating, Maintains Target Price $36.1
ZAI LAB (09688.HK) plans to hold a Board of Directors meeting on May 8 to approve the first-quarter performance.
Gelonghui reported on April 24 that ZAI LAB (09688.HK) announced that the Board of Directors' Audit Committee will review and approve on May 8, 2025 (Thursday) the company's and its subsidiaries' unaudited quarterly performance for the three months ending March 31, 2025, prepared in accordance with US Generally Accepted Accounting Principles and applicable rules of the USA Securities and Exchange Commission ("first quarter performance") and its release.
ZAI LAB: NOTICE OF AUDIT COMMITTEE ACTION AND DATE OF PUBLICATION OF FIRST QUARTER 2025 RESULTS ANNOUNCEMENT
Zai Lab To Present Data From Phase 1 Trial Of DLL3-Targeted Antibody-Drug Conjugate ZL-1310 At 2025 ASCO Annual Meeting